ESM1 suppresses LncRNA GAS5/miR-23a-3p/PTEN axis to promote the cisplatin-chemotherapy resistance of ovarian cancer cells via activating the PI3K/AKT pathway
Abstract Background Cisplatin chemotherapy is an important treatment for advanced ovarian cancer (OC). However, the development of cisplatin resistance greatly limits the survival time of OC patients. Endothelial cell-specific molecule 1 (ESM1) has been found to be an important proto-oncogene promot...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-03-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02113-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850094996734083072 |
|---|---|
| author | Hui Li Tingyu Fan Mei Qin Shuanghua Chen Wenchao Zhou Peiting Wu Yuwei Yuan Xing Tang Tian Zeng Jiawen Fang Ting Yi Juan Zhang Juan Zou Yukun Li |
| author_facet | Hui Li Tingyu Fan Mei Qin Shuanghua Chen Wenchao Zhou Peiting Wu Yuwei Yuan Xing Tang Tian Zeng Jiawen Fang Ting Yi Juan Zhang Juan Zou Yukun Li |
| author_sort | Hui Li |
| collection | DOAJ |
| description | Abstract Background Cisplatin chemotherapy is an important treatment for advanced ovarian cancer (OC). However, the development of cisplatin resistance greatly limits the survival time of OC patients. Endothelial cell-specific molecule 1 (ESM1) has been found to be an important proto-oncogene promoting OC, but its mediating OC cisplatin resistance remains unknown. Methods We used quantitative polymerase chain reaction (qPCR) to measure transcription levels of ESM1, Growth arrest specific transcript 5 (GAS5), miR-23a-3p, and Phosphatase And Tensin Homolog (PTEN). A double luciferase reporter gene assay confirmed the direct binding of GAS5 to miR-23a-3p and miR-23a-3p to PTEN mRNA. The effects of ESM1, GAS5, miR-23a-3p, and PTEN on OC cisplatin resistance were tested with an Half Maximal Inhibitory Concentration (IC50) assay. Flow cytometry was used to assess the effects of ESM1, GAS5, and miR-23a-3p on cisplatin-induced OC apoptosis. Changes in apoptosis-related proteins and PI3K/AKT-related proteins were analyzed with western blot (WB). Results ESM1 inhibits the levels of GAS5 and PTEN but increases miR-23a-3p. ESM1 and miR-23a-3p promote OC cisplatin resistance. GAS5 and miR-23a-3p promote cisplatin sensitivity for OC cells. Moreover, the main molecular mechanism is the ESM1/GAS5/miR-23a-3p/PTEN/PI3K/Akt signaling axis. Conclusion ESM1 promotes OC cisplatin resistance by activating the Phosphoinositide-3-Kinase (PI3K)/AKT Serine/Threonine Kinase (Akt) signaling pathway through the GAS5/miR-23a-3p/PTEN signaling axis. This suggests that prescriptive ESM1 regulates key downstream molecular mechanisms via non-coding RNA and can be used before neoadjuvant chemotherapy in OC is initiated. |
| format | Article |
| id | doaj-art-3586271c9af24c7cbd3d7255226f46df |
| institution | DOAJ |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-3586271c9af24c7cbd3d7255226f46df2025-08-20T02:41:32ZengSpringerDiscover Oncology2730-60112025-03-0116111310.1007/s12672-025-02113-1ESM1 suppresses LncRNA GAS5/miR-23a-3p/PTEN axis to promote the cisplatin-chemotherapy resistance of ovarian cancer cells via activating the PI3K/AKT pathwayHui Li0Tingyu Fan1Mei Qin2Shuanghua Chen3Wenchao Zhou4Peiting Wu5Yuwei Yuan6Xing Tang7Tian Zeng8Jiawen Fang9Ting Yi10Juan Zhang11Juan Zou12Yukun Li13Department of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South UniversityDepartment of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South UniversityDepartment of Gynecology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South UniversityHunan Traditional Chinese Medicine CollegeDepartment of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South UniversityDepartment of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South UniversityDepartment of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South UniversityDepartment of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South UniversityDepartment of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South UniversityNursing Class of 2022, School of Nursing, Heilongjiang University of Traditional Chinese MedicineTrauma Center, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South UniversityDepartment of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South UniversityDepartment of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South UniversityDepartment of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South UniversityAbstract Background Cisplatin chemotherapy is an important treatment for advanced ovarian cancer (OC). However, the development of cisplatin resistance greatly limits the survival time of OC patients. Endothelial cell-specific molecule 1 (ESM1) has been found to be an important proto-oncogene promoting OC, but its mediating OC cisplatin resistance remains unknown. Methods We used quantitative polymerase chain reaction (qPCR) to measure transcription levels of ESM1, Growth arrest specific transcript 5 (GAS5), miR-23a-3p, and Phosphatase And Tensin Homolog (PTEN). A double luciferase reporter gene assay confirmed the direct binding of GAS5 to miR-23a-3p and miR-23a-3p to PTEN mRNA. The effects of ESM1, GAS5, miR-23a-3p, and PTEN on OC cisplatin resistance were tested with an Half Maximal Inhibitory Concentration (IC50) assay. Flow cytometry was used to assess the effects of ESM1, GAS5, and miR-23a-3p on cisplatin-induced OC apoptosis. Changes in apoptosis-related proteins and PI3K/AKT-related proteins were analyzed with western blot (WB). Results ESM1 inhibits the levels of GAS5 and PTEN but increases miR-23a-3p. ESM1 and miR-23a-3p promote OC cisplatin resistance. GAS5 and miR-23a-3p promote cisplatin sensitivity for OC cells. Moreover, the main molecular mechanism is the ESM1/GAS5/miR-23a-3p/PTEN/PI3K/Akt signaling axis. Conclusion ESM1 promotes OC cisplatin resistance by activating the Phosphoinositide-3-Kinase (PI3K)/AKT Serine/Threonine Kinase (Akt) signaling pathway through the GAS5/miR-23a-3p/PTEN signaling axis. This suggests that prescriptive ESM1 regulates key downstream molecular mechanisms via non-coding RNA and can be used before neoadjuvant chemotherapy in OC is initiated.https://doi.org/10.1007/s12672-025-02113-1Ovarian cancerESM1GAS5PTEN/PI3K/AKT pathwayCisplatin resistance |
| spellingShingle | Hui Li Tingyu Fan Mei Qin Shuanghua Chen Wenchao Zhou Peiting Wu Yuwei Yuan Xing Tang Tian Zeng Jiawen Fang Ting Yi Juan Zhang Juan Zou Yukun Li ESM1 suppresses LncRNA GAS5/miR-23a-3p/PTEN axis to promote the cisplatin-chemotherapy resistance of ovarian cancer cells via activating the PI3K/AKT pathway Discover Oncology Ovarian cancer ESM1 GAS5 PTEN/PI3K/AKT pathway Cisplatin resistance |
| title | ESM1 suppresses LncRNA GAS5/miR-23a-3p/PTEN axis to promote the cisplatin-chemotherapy resistance of ovarian cancer cells via activating the PI3K/AKT pathway |
| title_full | ESM1 suppresses LncRNA GAS5/miR-23a-3p/PTEN axis to promote the cisplatin-chemotherapy resistance of ovarian cancer cells via activating the PI3K/AKT pathway |
| title_fullStr | ESM1 suppresses LncRNA GAS5/miR-23a-3p/PTEN axis to promote the cisplatin-chemotherapy resistance of ovarian cancer cells via activating the PI3K/AKT pathway |
| title_full_unstemmed | ESM1 suppresses LncRNA GAS5/miR-23a-3p/PTEN axis to promote the cisplatin-chemotherapy resistance of ovarian cancer cells via activating the PI3K/AKT pathway |
| title_short | ESM1 suppresses LncRNA GAS5/miR-23a-3p/PTEN axis to promote the cisplatin-chemotherapy resistance of ovarian cancer cells via activating the PI3K/AKT pathway |
| title_sort | esm1 suppresses lncrna gas5 mir 23a 3p pten axis to promote the cisplatin chemotherapy resistance of ovarian cancer cells via activating the pi3k akt pathway |
| topic | Ovarian cancer ESM1 GAS5 PTEN/PI3K/AKT pathway Cisplatin resistance |
| url | https://doi.org/10.1007/s12672-025-02113-1 |
| work_keys_str_mv | AT huili esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT tingyufan esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT meiqin esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT shuanghuachen esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT wenchaozhou esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT peitingwu esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT yuweiyuan esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT xingtang esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT tianzeng esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT jiawenfang esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT tingyi esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT juanzhang esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT juanzou esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway AT yukunli esm1suppresseslncrnagas5mir23a3pptenaxistopromotethecisplatinchemotherapyresistanceofovariancancercellsviaactivatingthepi3kaktpathway |